...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith 1-31-17 Interim Financials and Managements Discussion

I just did a quick scan of Zenith Epigenetics Financials recently posted on Sedar 

The Management Discussion and financials are perplexing

I just do not understand how the Chairman of the Board could float a value of $500mm in a recent presentation without justification

No valuation of Royalty Preferred shares in the financials means that the royalties are not reasonably determinable and the revenue stream at this point in time is not probable.

Hopefully the still awaited ZEN papers will unmask the mystery - 

 

Chicagoest 

Share
New Message
Please login to post a reply